Chernyshenko Tatiana, Polkin Roman, Dvoinikova Ekaterina, Shepelev Valeriy, Goncharuk Roman
Department of Surgery, Far Eastern Federal University, Vladivostok, Russia.
Medical Center, Far Eastern Federal University, Vladivostok, Russia.
Front Oncol. 2025 Feb 12;14:1526268. doi: 10.3389/fonc.2024.1526268. eCollection 2024.
Systematic review and update meta-analysis.
The present systematic review and meta-analysis were conducted to compare the efficacy and safety of the two approaches for HCC in adult patients (DEB-TACE vs cTACE).
The TACE procedure is indicated for the treatment of HCC with intermediate (BCLC B) and early (BCLC A). Conflicting data obtained from earlier meta-analyses comparing DEB-TACE with cTACE prompted the updated meta-analysis.
The study included adult patients over the age of 18 with HCC. MEDLINE conducted a literature search using Pubmed and Google Scholar up to May 2024. The following parameters were evaluated: the effectiveness of the tumor response to treatment according to the mRECIST criteria (CR, PR, SD, PD), overall survival, progression-free survival, and complication rate. 32 retro- and prospective studies were analyzed.
The study included 4,367 patients. The radiological response of the tumor in all four CR, PR, SD, and PD parameters in the DEB-TACE group showed the best response. The overall survival rate during the DEB-TACE procedure was higher by 3.54 months (p <0.00001), and progression-free survival (PFS) by 3.07 months (p <0.0001), respectively. The incidence of complications was comparable in both groups.
The results of the meta-analysis revealed clinically significant advantages of DEB-TACE in comparison with cTACE. Being comparable in terms of the frequency of complications, DEB-TACE demonstrated the best result in the radiological response of the tumor to the therapy, in terms of overall survival and progression-free survival.
系统评价与更新的荟萃分析。
进行本系统评价和荟萃分析以比较两种治疗成年肝癌患者方法(载药微球经动脉化疗栓塞术与传统经动脉化疗栓塞术)的疗效和安全性。
经动脉化疗栓塞术适用于治疗中期(巴塞罗那临床肝癌分期B期)和早期(巴塞罗那临床肝癌分期A期)肝癌。早期比较载药微球经动脉化疗栓塞术与传统经动脉化疗栓塞术的荟萃分析得到的相互矛盾的数据促使进行此次更新的荟萃分析。
该研究纳入年龄超过18岁的成年肝癌患者。截至2024年5月,利用PubMed和谷歌学术在MEDLINE中进行文献检索。评估了以下参数:根据改良实体瘤疗效评价标准(完全缓解、部分缓解、疾病稳定、疾病进展)评估的肿瘤治疗反应有效性、总生存期、无进展生存期和并发症发生率。分析了32项回顾性和前瞻性研究。
该研究纳入4367例患者。载药微球经动脉化疗栓塞术组在所有四个完全缓解、部分缓解、疾病稳定和疾病进展参数方面的肿瘤放射学反应显示出最佳反应。载药微球经动脉化疗栓塞术过程中的总生存期分别延长3.54个月(p<0.00001),无进展生存期延长3.07个月(p<0.0001)。两组并发症发生率相当。
荟萃分析结果显示,与传统经动脉化疗栓塞术相比,载药微球经动脉化疗栓塞术具有临床显著优势。在并发症发生率相当的情况下,载药微球经动脉化疗栓塞术在肿瘤对治疗的放射学反应、总生存期和无进展生存期方面显示出最佳结果。